Elan said it intends to continue to work with partner Biogen on realising the full potential of the multiple sclerosis drug Tysabri.
The biotechnology company's announcement comes after Biogen yesterday said it will remain an independent company after a search for a possible buyer failed to yield any definitive offers.
Elan said although it was not privy to the review done by Biogen since its October12th announcement, Elan had indicated its receptivity to a restructuring of its existing collaboration agreement in connection with a third party's acquisition of Biogen.